Cortical Surface Versus Penetrating BCIs
Precision Neuroscience
Precision is trying to win the part of the BCI market where enough signal quality matters, but full brain penetration is still too hard to scale. Its Layer 7 array sits on the cortex instead of being pushed into brain tissue, which makes it closer to standard cortical monitoring hardware, but its density is meant to capture far more spatial detail than vein based systems or conventional surface grids can provide.
-
Compared with Synchron, the difference is where the electrodes sit and how much brain activity they can sample. Synchron places a 16 electrode stent inside a blood vessel near motor cortex using a catheter procedure. Precision places a thin film directly on the brain surface, which is more invasive than vascular delivery but much closer to the signal source.
-
Compared with Neuralink, the trade is mostly about bandwidth versus tissue disruption. Neuralink records through 1,024 electrodes on threads inserted into brain tissue, which can reach single neuron level signals and higher performance ceilings, but requires robotic insertion into cortex. Precision gives up that deepest access in exchange for a simpler anatomical interface that does not puncture cortex.
-
Precision’s middle position is not just technical, it is regulatory and procedural. The FDA cleared Layer 7-T in March 2025 as a cortical electrode, and the company says it had tested the device in 37 patients by April 2025. That looks more like a path through existing neurosurgical workflows than a bet on entirely new robotic implantation infrastructure.
The next phase of competition will center on whether surface arrays can get close enough to penetrating systems on real world cursor control, typing, and speech decoding to become the more practical clinical default. If Precision can show that high density surface recording is good enough for daily use, it could define the mainstream middle of the implanted BCI market.